| abstract |
The present invention relates to new selective 5HT7 receptor binding benzofuran derivatives of general formula (I), wherein X represents a halogen atom or SO2NR1R2 group, wherein R1 and R2 represent, independently, a hydrogen atom, C1-6 alkyl group, C3-6 cycloalkyl group, phenyl group substituted with one or more halogen atom(s) or 1,7.7-trimethyl-bicyclo[2,2,1]hept-2-yl group, Y represents C2-6 alkylene group, optionally substituted with hydroxy group, A represents carbon atom, nitrogen atom or CH group, B represents CH or CH2 group, Q represents C1-4 alkyl group, a phenyl group optionally substituted with one or more halogen atom(s), C1-4 alkoxy group or trifluoromethyl group; phenylamino group substituted with a halogen atom or trifluoromethyl group; pyridine heterocycle; benzisoxazole or benzisothiazole heterocycle, optionally substituted with a halogen atom; benzimidazole or benzimidazolone heterocycle, optionally substituted with a halogen atom or trifluoromethyl group on the benzene ring, or optionally substituted on one of the N atoms with an C1-4 alkyl group; benzodioxane heterocycle, optionally substituted with a halogen atom on the benzene ring; pyridazinone heterocycle substituted with a halogen atom; dibenzothiazepine heterocycle or Q together with groups A and B represents a thiophene ring and their pharmaceutically suitable acid addition salts, with the proviso that if Y represents 2-hydroxy propylene group, A represents a carbon atom, B represents CH group, and Q represents 3-trifluoro-methyl-phenyl group, then X does not represent bromo atom. The invention extends to the process for producing said compounds, to pharmaceutical compositions containing said compounds and to their use in treatment and/or prevention of disorders of the central nervous system and cardiovascular system. |